Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
University of Alberta
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04580238CT.gov Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hemorrhagic Stroke
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Onabotulinum Toxin A (this asset) | University of Alberta | P1 | CC · 43 |
| Esmolol | Cristália Produtos Químicos Farmacêuticos Ltda. | P4 | BB |
| Atorvastatin | Duan Chuanzhi | P4 | BB |
| Cerebrolysin | Cardinal Stefan Wyszynski University | P4 | BB |
| Xingnaojing | Peking University Third Hospital | P4 | BB |
| Melatonin | Hospital San Carlos, Madrid | P4 | BB |
| Shuxuetong | Peking University Third Hospital | P4 | BB |
| Compound Solution Of Sodium Chloride | University Hospital Heidelberg | P2 | B |
| Enoxaparin | University Of Perugia | P3 | B |
+17 more in the Hemorrhagic Stroke cohort
Other indications for Onabotulinum Toxin A
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Migraine Disorder | — | P4 | BB · 66 |
| Neuralgia | — | P2 | CCC · 53 |
| Multiple Sclerosis | — | P4 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Onabotulinum Toxin A in Hemorrhagic Stroke. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/onabotulinum-toxin-a-hemorrhagic-stroke
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →